Market Cap 152.87M
Revenue (ttm) 0.00
Net Income (ttm) -19.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 42,300
Avg Vol 103,120
Day's Range N/A - N/A
Shares Out 25.46M
Stochastic %K 49%
Beta -0.29
Analysts Strong Sell
Price Target $18.00

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, Suite 275, Fort Lee, United States
mmtiddy
mmtiddy Oct. 2 at 10:57 AM
$NVCT Starting a small position, will add if it continues to drop, but seems well established at accumulation zone Catalysts for next year, cash runway till Q1 2027 Good insider purchases in the last 12 months
0 · Reply
BioTrade2
BioTrade2 Oct. 2 at 2:12 AM
$NVCT more reading https://aacrjournals.org/cancerres/article/81/21/5438/670511/A-Conformation-Selective-Mode-of-Inhibiting-SRC
1 · Reply
BioTrade2
BioTrade2 Oct. 1 at 6:23 PM
$NVCT read it. Understand it https://pubmed.ncbi.nlm.nih.gov/32466572/
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:13 PM
$RC Ready Capital: 202 trades, $126K vs $19K avg (6.62x). $15K calls / $111K puts. $EUAD Spinnaker ETF Europe Aero & Defense: 48 trades, $16K vs $36K avg (0.44x). $15K calls / $1K puts. $NVCT Nuvectis Pharma: 4 trades, $14K vs $13K avg (1.13x). $14K calls / $0 puts. $STC Stewart Information Services: 3 trades, $14K vs $13K avg (1.14x). $14K calls / $0 puts.
0 · Reply
buyandsold
buyandsold Sep. 29 at 8:58 PM
$NVCT very cheap given they will cure cancer
0 · Reply
BioTrade2
BioTrade2 Sep. 26 at 1:07 AM
$NVCT IMRX PRQR XAIR What do these all have in common? We’re not in good company. Jordan had an amazing call on AXSM, but just about everything after that has been a dud.
1 · Reply
WallStWireAds
WallStWireAds Sep. 25 at 12:03 PM
$NVCT https://caplynx.io/CgvV3el
0 · Reply
essiepaul
essiepaul Sep. 24 at 2:45 PM
$NVCT welcome to tax loss season. Expecting $5’s from this gem unless they put out some decent news
1 · Reply
BioSensai
BioSensai Sep. 19 at 8:06 PM
$NVCT Guess who is back ;) Data likely will begin trickling in q2-26
1 · Reply
UNLV
UNLV Sep. 19 at 6:37 PM
$NVCT 1b expansion slated start later this year. Management huge shareholders and going all-in testing many/all indications in one trial High selectivity, high concentration during entire 24 hour dosing and no dose limiting toxicity
1 · Reply
Latest News on NVCT
Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference


Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash


Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND


mmtiddy
mmtiddy Oct. 2 at 10:57 AM
$NVCT Starting a small position, will add if it continues to drop, but seems well established at accumulation zone Catalysts for next year, cash runway till Q1 2027 Good insider purchases in the last 12 months
0 · Reply
BioTrade2
BioTrade2 Oct. 2 at 2:12 AM
$NVCT more reading https://aacrjournals.org/cancerres/article/81/21/5438/670511/A-Conformation-Selective-Mode-of-Inhibiting-SRC
1 · Reply
BioTrade2
BioTrade2 Oct. 1 at 6:23 PM
$NVCT read it. Understand it https://pubmed.ncbi.nlm.nih.gov/32466572/
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:13 PM
$RC Ready Capital: 202 trades, $126K vs $19K avg (6.62x). $15K calls / $111K puts. $EUAD Spinnaker ETF Europe Aero & Defense: 48 trades, $16K vs $36K avg (0.44x). $15K calls / $1K puts. $NVCT Nuvectis Pharma: 4 trades, $14K vs $13K avg (1.13x). $14K calls / $0 puts. $STC Stewart Information Services: 3 trades, $14K vs $13K avg (1.14x). $14K calls / $0 puts.
0 · Reply
buyandsold
buyandsold Sep. 29 at 8:58 PM
$NVCT very cheap given they will cure cancer
0 · Reply
BioTrade2
BioTrade2 Sep. 26 at 1:07 AM
$NVCT IMRX PRQR XAIR What do these all have in common? We’re not in good company. Jordan had an amazing call on AXSM, but just about everything after that has been a dud.
1 · Reply
WallStWireAds
WallStWireAds Sep. 25 at 12:03 PM
$NVCT https://caplynx.io/CgvV3el
0 · Reply
essiepaul
essiepaul Sep. 24 at 2:45 PM
$NVCT welcome to tax loss season. Expecting $5’s from this gem unless they put out some decent news
1 · Reply
BioSensai
BioSensai Sep. 19 at 8:06 PM
$NVCT Guess who is back ;) Data likely will begin trickling in q2-26
1 · Reply
UNLV
UNLV Sep. 19 at 6:37 PM
$NVCT 1b expansion slated start later this year. Management huge shareholders and going all-in testing many/all indications in one trial High selectivity, high concentration during entire 24 hour dosing and no dose limiting toxicity
1 · Reply
UNLV
UNLV Sep. 17 at 5:29 PM
$NVCT looking at LOCATIONS finds all USA locations recruiting. UK locations completed trial. Let's remember insider Charles was buying big.....company knows UK results and UK research led early development Study Details | NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | ClinicalTrials.gov https://share.google/qJq9pHRd6QvpAOtr9
1 · Reply
highnihilism
highnihilism Sep. 16 at 7:06 PM
IWM: Russell 2000 → $NVCT Nuvectis Pharma $GRND Grindr $MYO Myomo $JOE St. Joe $BNED Barnes & Noble
0 · Reply
BioTrade2
BioTrade2 Sep. 16 at 6:55 PM
$NVCT what have they achieved over the last 4 years? Only started mono therapy 900 trial. That’s it. Have owned it since ‘22, nothing to show for it. Meanwhile so many companies in XBI skyrocketed. We’re always 6-9 months away from earth shattering data.
1 · Reply
essiepaul
essiepaul Sep. 15 at 10:06 PM
$NVCT under performer is being nice with this ticker. Just a brutal hold for multiple yrs as market rockets north
1 · Reply
buyandsold
buyandsold Sep. 12 at 6:40 PM
$NVCT nasty action
0 · Reply
WallStWireAds
WallStWireAds Sep. 11 at 2:53 PM
$NVCT https://capnotes.beehiiv.com/p/nuvectis-pharma-s-nxp900-may-be-the-cancer-treatment-breakthrough-that-big-pharma-has-been-chasing-f
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 7:16 PM
$NVCT Really good write-up that perfectly summarizes NVCT's present situation. So if you want to bring your NVCT knowledge up to date or just discover NVCT, this is required reading. https://beyondspx.com/quote/NVCT/analysis/nuvectis-pharma-s-high-stakes-pivot-nxp900-takes-center-stage-in-precision-oncology-nasdaq-nvct
0 · Reply
biospeculator
biospeculator Sep. 5 at 2:38 PM
$NVCT New Truffle Pig analysis is out. Their timing and pps predictions to date have been too optimistic. However, their thesis of value for the NXP900 drug IF proven in trials are imo very interesting. I am long.
1 · Reply
WallStWireAds
WallStWireAds Sep. 4 at 11:31 AM
$NVCT https://caplynx.io/2MLQZfm
0 · Reply
tasha655
tasha655 Sep. 2 at 5:38 PM
0 · Reply
tasha655
tasha655 Aug. 26 at 5:08 PM
$NVCT this will be $10
0 · Reply
biospeculator
biospeculator Aug. 24 at 2:15 PM
$NVCT From a technical standpoint, I clearly see a wave II completion in a typical abc pattern. IF so then we are about to enter wave III which should equal 2x wave one. Wave I was $4.5-$11.5 or $7. Therefore, under Elliot wave theory wave III should be $14 or a target of $20. Looking at the 3 year chart, we see that target is exactly the previous high. MY TARGET FOR THIS MOVE IS $20! glta
0 · Reply